- Home
- ACIC vs PLRX Comparison
ACIC vs PLRX Comparison
Compare ACIC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | PLRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.4M | 73.7M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACIC | PLRX |
|---|---|---|
| Price | $9.31 | $1.15 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 242.3K | ★ 401.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | 29.97 |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | $11.49 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.10 | $1.02 |
| 52 Week High | $13.06 | $1.95 |
Technical Indicators
Market Signals| Indicator | ACIC | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 54.63 |
| Support Level | $9.10 | $1.12 |
| Resistance Level | $9.68 | $1.26 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 44.83 | 53.18 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.